Abstract There have been many advances in anterior cruciate ligament reconstruction (ACLR) techniques incorporating biological treatment. The aim of this review is to discuss the recent contributions that may enlighten our understanding of biological therapies for anterior cruciate ligament (ACL) injuries and improve management decisions involving these enhancement options. Three main biological procedures will be analyzed: bio-enhanced ACL repair, bio-enhanced ACLR scrutinized under the four basic principles of tissue engineering (scaffolds, cell sources, growth factors/cytokines including platelet-rich plasma, and mechanical stimuli), and remnant-preserving ACLR. There is controversial information regarding remnant-preserving ACLR, since different procedures are grouped under the same designation. A new definition for remnant-preserving ACLR surgery is proposed, dividing it into its three major procedures (selective bundle augmentation, augmentation, and nonfunctional remnant preservation); also, an ACL lesion pattern classification and a treatment algorithm, which will hopefully standardize these terms and procedures for future studies, are presented.
Introduction
An anterior cruciate ligament (ACL) tear is a common lesion and may become functionally disabling, as well as increasing cartilage loading. Still, there is no consensus that anterior cruciate ligament reconstruction (ACLR) prevents osteoarthritis, but it is known that, once cartilage composition is damaged and load-bearing exceeds the low healing response of the tissue, there is increased catabolism and progression to osteoarthritis even in normal knees subjected to augmented mechanical stimuli [1] [2] [3] . ACLR is a common orthopedic procedure. There have been many advances in ACLR techniques in the last few years, in part because of a better understanding of the ligament anatomy and a transition from the so-called isometric reconstruction to anatomic reconstruction of the ACL [4, 5] . Despite these advances, ACLR is not a universally successful procedure and has actual failure rates around 8 % [5] .
While there are a lot of biological treatment options for knee injuries and a surprisingly high number of new strategies and techniques appearing constantly, there is no consensus regarding the advantage of one over another. Most of the current biological solutions are in the field of tissue engineering. The four basic components of this field are biomaterial scaffolds, cell sources, growth factors/cytokines, and mechanical stimuli. These are being applied to the development of tissue-engineered ACL replacement grafts and tissueengineered ACL repair [6] .
The aim of this review is to discuss the recent contributions to the literature that may enhance our understanding of biological therapies for ACL injuries and their outcomes, in comparison with the established knowledge based in classical treatments. The primary focus of this article are biological solutions for biological problems that lead to less invasive procedures, accelerated and enhanced healing, reduced morbidity, and optimized recovery [7] .
Chronology and pattern of musculoskeletal research
Since 1977, musculoskeletal research has undergone four phases. In phase 1, between 1977 and 1985, organ-/tissuelevel research focused on human cadaveric knee and ligament function, as well as factors affecting anterior cruciate ligament structure-function relationship and reconstruction. In phase 2, between 1986 and 1994, the focus turned more to the tissue level, with studies of structure-function relationship and soft tissue healing. In phase 3, between 1995 and 2003, research moved to the tissue/cell level; nonetheless, in vivo tissue forces continued to be studied, and the first studies identifying novel therapies in tissue engineering and functional tissue engineering emerged. In phase 4, between 2004 and 2012, a progression to the tissue/cell/molecular levels has occurred in search of developing not only design criteria for tissueengineered tendon and ligament repairs, as compared with normal tissues, but also new research directions in fundamental tissue engineering at the interface of functional tissue engineering and developmental biology [8] .
ACL healing response after injury
To better appreciate biological therapies for an ACL lesion, it is first necessary to understand its healing response after injury. ACL response to injury is different from that reported in other dense connective tissues, particularly by three critical features: formation of a thin synovial cell layer on the surface of the ruptured ends, the lack of any tissue bridging the rupture site as the blood clot dissipates in the synovial fluid preventing the formation of a hematoma and a provisional scaffold, and the presence of an epiligamentous reparative phase that lasts 8-12 weeks. Unlike extraarticular ligaments that heal after injury, the human intraarticular ACL forms a layer of synovial tissue over the ruptured surface, which may hinder the repair of the ligament by the lack of a provisional scaffold associated to decreased important extracellular matrix proteins, cytokines, and growth-factors involved in ligament healing [9] [10] [11] . Moreover, ACL fibroblasts are also different from other ligaments having lower mobility, proliferation, metabolic activities, and matrix production rates. Additionally, they exhibit higher matrix metalloproteinases activity and poor adhesive strength [9] . All these characteristics are responsible for the low healing potential of a torn ACL ligament.
Bio-enhanced ACL repair
Given the low ACL healing potential and the poor results of ACL repair, being no different from conservative treatment, there have been many efforts trying to enhance ACL repair with biological therapies, with successful and promising results in experimental studies still not translated into clinical practice.
The initial precursor experimental studies of bio-enhanced repair found that a tissue-engineered composite like extracellular-matrix-based scaffolds or collagen-based composites and platelet-rich-plasma (PRP) stimulated healing in an ACL central defect. These studies led to combining these biological enhancements with a suture repair of the torn ACL, leading to a bio-enhanced ACL repair. Later it was determined that the association of an enhanced PRP extracellular-matrixbased scaffold ACL repair could achieve better results than the extracellular matrix scaffold enhanced repair alone or just the PRP enhanced repair. This association maintained and activated the platelets in the lesion, releasing growth factors that matched their release in extraarticular ligament healing, attaining results similar to a compared ACLR in the same animal models [10, [12] [13] [14] [15] . It is important to note that there are variations in the technique employed, since using an extracellular matrix hydrogel associated to the extracellular matrix scaffold bio-enhanced repair. The hydrogel has the theoretical function of recruiting growth factors like the PRP [16] .
Further studies have shown that ACL healing with extracellular-matrix-based scaffolds is dependent on age and time from injury to repair, with younger animals and shorter time from injury demonstrating a better healing capacity [10, 17, 18] . Also of note, the cells that migrate out of the human torn ACL constitute a rich population of progenitor cells that display mesenchymal stem cell (MSC) characteristics that have the potential to provide the basis for a superior, biological repair of this ligament [19] . Clinical implications of these findings include the encouraging potential of a new treatment: ACL bio-enhanced repair, particularly attractive in the pediatric population and for acute lesions.
Bio-enhanced ACL reconstruction

Biomaterial scaffolds
The ideal tissue-engineered ACL graft scaffold should be biocompatible, with mechanical strength similar to the native ACL, and have biodegradable properties to allow tissue ingrowth and facilitate cellular processes required for the healing of the new ACL. Common biomaterials include collagen, silk, hyaluronic acid, chitosan, alginate, polydioxanone, poly-glycolic acid (PGA), poly-L-lactic acid, poly-caprolactone (PCL), and polylactic-co-glycolic acid (PLGA) [6] .
Below, some experimental studies of new biomaterial scaffolds and their manufacture techniques developed in the recent years will be exposed. Phenotypic responses of human ACL cells on two biodegradable materials were analyzed: PCL and chitosan. ACL cells cultured on PCL displayed phenotypes that were well spread with a developed cytoskeleton. In comparison, chitosan was not an appropriate substrate to support the attachment and spreading of ACL cells; this was attributed to the low fibronectin adsorption of chitosan. However, ACL cells cultured on chitosan exhibited increasing transcripts of transforming growth factor (TGF) beta1 and collagen III. After coating fibronectin on a chitosan surface, cell morphology and the mRNA levels of all tested genes had similar levels of PCL and fibronectin-coated chitosan. This indicated that the expression of TGF beta1 and collagen III mRNA of human ACL cells seemed to correlate closely with the adhesion behavior of human ACL cells and was influenced by the underlying substrate properties. Since an ideal scaffold used in ACL tissue engineering is not only for cell attachment, but also for extracellular matrix deposition during ligament regeneration, chitosan may be considered as a potential scaffold for ACL tissue engineering, which can upregulate the expression of specific genes of matrix production and wound healing in human ACL cells to synthesize a greater amount of fibronectin and TGF beta1 proteins [20] .
Chitosan scaffolds can enhance human ACL cells to increase the gene expression of TGF beta1, which is a specific gene for wound healing and collagen synthesis [20] . However, human ACL cells could not adhere and proliferate well on chitosan. In order to overcome this drawback, PCL was introduced into chitosan. It was found that the morphology, viability, and gene expression of human ACL cells on the chitosan/ PCL blends could be effectively regulated. With the increase of PCL content in the blends, human ACL cells presented a more flattened shape, a well-organized cytoskeleton, and higher proliferation ability. Therefore, it was possible to influence human ACL fibroblast morphology and gene expression by altering the ratios of polycaprolactone to chitosan in blended scaffolds [20] .
Polymeric nanofiber scaffolds are potential alternatives to autografts and allografts. The fibers making up these scaffolds can be designed to closely match the structure of the native extracellular matrix by mimicking the dimensions of the collagen fiber bundles in soft connective tissues. These nanostructured implants show improved biological performance, while maintaining favorable mechanical properties, as compared with the bulk materials, in regard to cellular infiltration and in vivo integration; the topography of such scaffolds has been shown to dictate cellular attachment, migration, proliferation, and differentiation, which are critical steps in engineering complex functional tissues and crucial to improved biocompatibility and functional performance. Nanofiber matrices can be fabricated using a variety of techniques, including drawing, molecular self-assembly, freeze-drying, phase separation, and electrospinning. Among these processes, electrospinning has emerged as a simple, elegant, scalable, continuous, and reproducible technique for producing polymeric nanofiber matrices from solutions and their melts. This technique produces ultrafine fibers by drawing a polymer solution onto a collecting plate and using an electrical charge to fabricate matrices composed of fibers from a few hundred nanometers to several microns in diameter by simply altering the polymer solution concentration. Electrospinning polymeric nanofiber matrices have gained increased popularity in the past decade in the field of tissue engineering [21• ].
An electrospun PCL nanofiber matrix surface functionalized with poly[(ethyl alanate), (p-methyl phenoxy)] phosphazene was fabricated for the purpose of achieving soft skeletal tissue regeneration. A preliminary study reported the effect of fiber diameter and polyphosphazene surface functionalization on significant scaffold properties such as morphology, surface hydrophilicity, porosity, tensile properties, human mesenchymal stem cell adhesion, and proliferation. It was found that improving PCL matrix hydrophilicity via proposed surface functionalization might be an efficient method for improving cell-PCLmatrix interactions [22] .
Blends of hydrophobic PCL and hydrophilic PGA-PCL-PGA triblock copolymer were electrospun into scaffolds [23] . Varying the ratios of PCL and PGA-PCL-PGA copolymer can control hydrophilicity, mechanical strength, and degradation rate properties. A finite element analysis was described to analyze the optimal configuration for a braided copoly (lactic acid-co-(E-caprolactone)) (PLCL) scaffold [24] .
A water-soluble chitosan derivative, carboxymethyltrimethylchitosan, was synthesized, and a RGD-peptide was grafted to the backbone to increase cell-biomaterial interaction. The developed polymer showed good biocompatibility, and the initial adhesion was increased by 3-5 times. Moreover, cell spreading was specific to the interaction with RGD-peptide, giving a 12-fold increase of cells showing a fully spread morphology within 30 min. Overall, the developed polymer may prove useful as a biomaterial in wound healing [25] .
The extracellular matrix of tendons and ligaments is composed basically by collagen fibrils, and, in healthy tissues, larger diameter fibrils are present in an organized pattern. Injured tissues have smaller diameter fibrils with a disorganized pattern, and this may lead to a worsening of the healing response and biomechanics properties, mainly the tensile strength. A previous study [26•] has demonstrated a relationship between scaffold fiber diameter and human tendon fibroblast culture modulation. Polymeric PLGA scaffolds were fabricated by electrospinning: Nanofiber-scale scaffolds stimulated matrix deposition, and microfiber-scale scaffolds led to an upregulation of phenotypic markers. These results demonstrate that scaffold fiber diameter is an important factor to be taken into account in connective tissue repair [26•] .
Basically, polymer selection is crucial to determining the mechanical properties and degradation rate of the scaffold, whereas different manufacturing methods can be used to alter the micro-and macrostructure of the ACL graft [6] .
Cell sources An optimal cell source for ligament tissue engineering must have a capacity to proliferate and produce an extracellular matrix similar to the native ligament. Ligament fibroblasts would be an excellent option if they were more numerous and had a better proliferative potential. More and more, stem cells are being investigated as a substitute for fibroblasts, given their pluripotential capability to differentiate. Stem cell applications rely on the MSC plasticity potential for differentiation into cells of the mesodermal lineage. MSCs can be extracted from various tissues (bone marrow, adipose tissue, synovial membrane, periosteum, trabecular bone, umbilical cord blood, amniotic fluid, Wharton's jelly, and skeletal muscle) and expanded. The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy has defined the following minimal set of standard criteria for uniform characterization of MSCs: They must be plasticadherent cells when maintained in standard culture conditions; they must express CD105, CD73, and CD90; they must lack surface expression of CD45, CD34, CD14 (CD11b), CD79α (CD19), and HLA-DR; and they must be capable of differentiating to cells of the mesodermal lineage (chondrocytes, osteoblasts, adipocytes). The most commonly used MSCs in ligament-healing studies are the ones derived from bone marrow and the ones derived from the ligament itself, along with its healing process. Of note is the unsuitability of adipose-derived stem cells for bio-enhanced ligament healing [6, 27, 28] .
Human ACL-ruptured tissue contains abundant vascular stem cells that contribute to tendon-bone healing in an immunodeficient rat model of ACL reconstruction. Following this, transplantation of ACL-ruptured tissue, which was sutured to the tibial side of the graft, contributed to early tendon-bone healing in an experimental study [29] . ACL-derived CD34(+) cells contribute to tendon-bone healing after ACL reconstruction via the enhancement of angiogenesis and osteogenesis, which also contributed to an increase in biomechanical strength, in another experimental study, suggesting a specific potential cell source type for ligamentization improvement [30] . A subsequent study with ACL-derived CD34+ cell sheet wrapped grafts demonstrated a greater number of cells derived from the cell sheets incorporated within the bone tunnel site and grafted tendon, reaffirming that this strategy can possibly enhance proprioceptive recovery, graft maturation, and biomechanical strength [31] .
Continual experimental studies are being made to define the best situation fitted to promote bio-enhanced ligament healing using MSCs. Despite their higher proliferative potential, MSCs presented better results when combining their use in a 50 % co-culture of ACL cells and MSCs, instead of either cell population alone, demonstrating better maintenance or even enhancing ligament marker expression and improved healing [32• ]. An MSC-based tissue-engineering strategy applied at the time of surgery can be used to accelerate and enhance osseous integration of the graft tissue by providing a cellular component involved at ligament healing. A novel human MSC population derived from the hemarthrosis fluid within the joint at injury was identified [33, 34] . The osteogenic response of this hemarthrosis-derived MSC was later proved to be enhanced when cultured with PLGA, as compared with control cultures, which can lead to an enhanced osseous integration of soft tissue grafts during ligament reconstruction [35] .
Finally, preserving small amounts of muscle on tendon grafts was feasible for improving the biological success of ACLR in one experimental study demonstrating improved healing, intraarticular incorporation, vascularity, cellularity, failure load, yield load, and elongation at failure [36] .
Growth factor/cytokine augmentation A complex cascade of cytokines, being it bone to bone or tendon to bone, regulates graft-bone healing. The main chemical regulators are currently believed to include the TGF family, bone morphogenic protein (BMP) family, insulin-like growth factor family, matrix metalloproteinases, fibroblast growth factors, vascular endothelial growth factors, and platelet-derived growth factors (PDGFs) [37] . Starting in the late 1990s, there has been a great effort to understand these cytokines and their relationship to ligamentization, culminating in a great numbers of related studies, although attention has decreased in the last few years.
TGF-β is a key regulator during embryologic tendon development and also plays a significant role in the modulation of scar tissue formation during connective tissue healing [37] . Increased TGF-β1 facilitates the ACL healing process by promoting the fibroblasts migration and proliferation [38] . The BMP molecules are osteoinductive cytokines related to the TGF-β family [37] . The pCMV-BMP-2 gene therapy significantly improved the healing of tendon to bone and promoted angiogenesis and osteogenesis at the tendon-bone interface after ACL reconstruction [39] .
MMPs are zinc-dependent enzymes that are present in the connective tissue and are activated from their latent form via a cleavage mechanism, regulating and maintaining the dynamic homeostasis of the extracellular matrix of connective tissues. Tissue inhibitors of MMP proteins, which assist in coordinating a balance of matrix regeneration and remodeling, balance their enzymatic activity. MMP production and activation are increased in the presence of inflammatory signals such as interleukin 1b (IL-1b) and TGF-β1, serving as a key component of the early inflammatory and repair phases of healing [37] . Increased TGF-β1 facilitates ACL's healing process by promoting fibroblasts migration and proliferation. Fibroblast migration is mediated by MMP-2, and NF-κB pathway is involved in TGF-β1-mediated MMP-2 release that leads to an augmented fibroblast migration and proliferation [38] .
Platelet rich plasma (PRP)
PRP has the so-called biological enhancement or augmentation effect, since platelets contain alpha granules that are rich in growth factors involved in hemostasis and healing processes. PRP has a higher than normal concentration of platelets aiming to optimize the healing response. Care must be taken relative to the variety of systems, methodologies, and consequent final compositions of PRP, because some of the current systems are not reliable. There are a lot of experimental data encouraging its use in clinical practice, demonstrating a better healing response related to the graft incorporation, but unfortunately, to date, there is no evidence-based medicine data supporting the use of PRP in treatment of ACL, and there is still the fundamental need for standardization of its preparation methods [40, 41, 42••] . The only ACLR improvement proved so far by PRP is not directly related to healing enhancement in ligamentization, but to reducing donor site pain at the patellar tendon harvest site [43, 44] .
Mechanical stimuli
Different tunnel placements seem to be associated with different outcomes, since different mechanical stimuli affect graft ligamentization. Knee stability and cartilage incident forces are displayed in distinctive ways related to anatomical and nonanatomical ACL reconstruction. As already stated, given the better understanding of ACL anatomy, there has been a transition from the so-called isometric reconstruction to anatomic reconstruction of the ACL [4, 5] . Allegedly, some studies pointed out that anatomical tunnel placement results in superior biological healing, biomechanical properties, knee stability, and even a protective cartilage effect, as compared with a nonanatomic reconstruction [45] [46] [47] [48] [49] .
MSC differentiation can be driven primarily by chemical stimulation; nonetheless, it has already been demonstrated that more easily controllable features, such as scaffold fiber alignment and optimized mechanical stimulation, are sufficient to drive MSC differentiation, without the need for additional chemical stimuli [50•] .
Finally, representing the synthesis of tissue-engineering basic principles and the recent trends in this field are the combined application and investigation of all the factors together: biomaterial scaffolds, cell therapy, growth factors, and mechanical stimulation. A typical example is the study of 
Remnant-preserving ACLR
The definition of remnant-preserving ACLR surgery is controversial because it currently refers to the following three major procedures: selective bundle augmentation (SBA) ACLR in a partial lesion, involving either the posterolateral or anteromedial bundle with functional remaining fibers; augmentation (AG) ACLR in a partial lesion, involving one or both bundles with some remaining functional tissue; and ACLR in a complete lesion, involving both bundles with some remaining nonfunctional tissue (NFRP-nonfunctional remnant preservation) [51] [52] [53] [54] [55] [56] 57 Partial ACL tears are frequent (5 %-38 %) [62•] , and the remnant fibers have been given more importance in recent years. ACLR using a remnant-preserving technique also called ACL augmentation supposedly improves the ligamentization process, since the remnant functional fibers may biomechanically protect the graft, the vascularized remnant synovial envelope may enhance vascularization, and the valve mechanism created by the remaining tissue and the tunnel may inhibit the entry of synovial fluid, resulting in less tunnel enlargement; also, histological studies have shown mechanoreceptors in the remaining tissue that may optimize proprioceptive function [52, 54, 55, 57••, 58, 59 •, 62•, 63••, 64, 65] .
In this review, we would like to introduce a new definition for remnant-preserving ACLR surgery, categorizing it into its three major procedures (SBA, AG, NFRP) and also presenting a novel ACL lesion pattern classification system that will hopefully standardize these terms and procedures for future studies and metaanalyses, based primarily on the classification of Crain et al. [55] .
Previous studies have noted that arthroscopic evaluation and characterization of the remaining fibers as functional or nonfunctional by probe palpation is more important than identifying the injured bundle or determining the percentage of torn ACL fibers [54, 56] . Attempts to attenuate or elongate the fibers, sometimes in the "figure of four" position, and evaluating the posterolateral bundle can be difficult and should be conducted by probe palpation [54, 56] .
When classifying the ACL lesion pattern using functional arthroscopic evaluation, we recommend using a new staged method based on descriptive terms defined in the current literature for the remnant tissue present, morphology, and functionality [51, 53-56, 60, 66] . These descriptive terms include the following: (1) remaining tissue: totally disappeared, remnant present; (2) remnant morphology type: tibial stump (I), scarring to the PCL (II), scarring to the roof notch (III), unidentifiable bundle pattern scarring to the lateral femoral condyle (IV), anteromedial bundle (IV), posterolateral bundle (VI); (3) remnant functionality: functional, nonfunctional (Fig. 1) .
After ACLR, steps 1 to 3 must be repeated, since some remaining tissue may be damaged during surgery, changing its initial status, and the type of remnant-preserving reconstruction determined: SBA, AG, or NFRP. In both AG and NFRP, the graft may be passed in the periphery of the tibial footprint preserving the remnant and passing side-by-side with it or be passed through the center of the tibial remnant being enveloped and wrapped by the remaining tissue that acts as a biological sleeve. The percentage of graft coverage with the remnant tissue should be also documented (Fig. 2) .
Better tunnel placement using the remaining tissue as a reference could be expected with SBA. Tunnel placement, however, is more demanding in all three types of procedures, as compared with the standard surgery with remnant debridement, and sometimes fluoroscopy confirmation of its correct placement is necessary [51, 54, 60] . Biomechanical protection of the graft by the intact fibers is an advantage in SBA and AG; however, intact functional fibers that provide this type of protection are not present in NFRP [55, 67] .
Several studies discuss the potential for improved stability by preserving the remaining tissue through either direct mechanical protection of the graft or improved graft vascularization, which would optimize ligamentization. Regarding the three types of remnant-preserving ACL surgeries, SBA is believed to provide better knee stability results, followed by AG and, lastly, by NFRP [51] [52] [53] [54] [55] [56] 57 Tunnel enlargement is caused by high levels of cytokines and inflammatory agents in the postsurgery synovial fluid bathing the tunnel graft-bone interface and micro-motion in this environment; also, tunnel enlargement is more common in the tibia consequent to gravity. Although a correlation between tunnel enlargement and clinical outcomes has not been conclusively demonstrated, it remains a concern in revision surgery. The remnant-preserving technique results in less tibial tunnel enlargement allegedly because of the valve mechanism created by the remaining tissue and the tunnel, which inhibits the entrance of synovial fluid [57••, 63••] .
Several studies have evaluated remnant-preserving ACLR surgery or compared it with standard ACLR with debridement of the remaining tissue. However, because of inconsistent results and varying methodologies, we will show only the main randomized controlled trials comparing both methods. One study [62•] (Table 1) .
Evidence currently remains limited but suggests that remnant-preserving ACLR surgery and ACL standard remnant debridement surgery produce similar functional and stability results. However, further studies with an adequate sample size, standardized reconstruction definitions (SBA, AG, or NFRP), and ideal robust methodology with randomized controlled trials must be conducted to confirm the theoretical advantages pointed out by lots of lower evidence level studies [51-54, 56, 60, 61, 66, 67] .
More recent studies analyzing human samples have emphasized the potential of remnant tissue preservation ligamentization improvement, particularly the synovium as a healing enhancement MSC source for ACL regeneration. This remaining tissue potential capacity is inversely correlated with injury chronicity, suggesting better outcomes in the remnant-preserving ACLR techniques applied in the more acute settings [68] [69] [70] . 
Conclusions
Biological therapies are being developed and analyzed to optimize ACL injury treatment. Promising results of experimental studies point out a potential bio-enhanced ACL repair as a feasible future treatment option particularly attractive to pediatric populations and acute lesions. Bio-enhanced ACL reconstruction is a field of constant evolution marked by the four evolving cornerstones of tissue-engineering applications and its positive effects in ligamentization: biomaterial scaffolds, cell sources, growth factors/cytokines, and mechanical stimuli. Remnant-preserving ACLR has increased in popularity, given the better understanding of the potential benefits of the remaining tissue and the increasing number of articles, predominantly low evidence level clinical studies exhibiting encouraging results.
Despite a great number of studies in bio-enhanced ACL repair and bio-enhanced ACL reconstruction, the vast majority are experimental studies; there seems to be a lack of translational progression to clinical studies in both fields, principally in the bio-enhanced ACL repair. Remnantpreserving ACLR is a field of more consistent clinical data, with a few randomized clinical trials; however, there is an urgent need for better definition and standardization of its types, enabling pooled data meta-analysis providing robust evidence-based conclusions. In future studies, we recommend using the definitions for the three major ACLR techniques using remnant-tissue-preserving techniques (SBA, AG, NFRP) and the ACL lesion pattern classification system proposed in this review.
Under the concept of biological therapy, remnantpreserving ACLR seems to be the most simple, easily available, and economically viable strategy to improve ACL treatment. The authors strongly recommend utilizing a remnantpreserving ACLR technique in the presence of remnant fibers, believing that this type of procedure will soon be evidencebased recommended over the standard ACLR with remnant debridement. Note. ACLR, anterior cruciate ligament reconstruction; AG, augmentation; SBA, selective bundle augmentation; AM, anteromedial; NFRP, nonfunctional remnant preservation; BPTB, bone-patellar tendon-bone; IKDC, International Knee Documentation Committee; KOOS, knee injury and osteoarthritis outcome; ROM, range of motion
